Abstract
Multiple myeloma (MM) is a chronic plasma cell malignancy with a median survival of about 8–10 years. Despite the development of many new drugs in recent years, disease recurrence is inevitable. The current critical unmet need is the management of heavily pretreated patients with refractory MM....

This publication has 17 references indexed in Scilit: